The Recall Desk
ModerateFDA (Drugs)·D-0649-2016·Announced 2016-02-10

Pfizer Recalls Lyrica Pregabalin Capsules for Deformed or Damaged Units

Pfizer is recalling specific lots of Lyrica (pregabalin) 75 mg capsules due to the potential presence of deformed or damaged capsules.

What this means for you

Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.

Our severity reasoning: The recall is classified as FDA Class II, and the hazard involves physical defects (deformed/damaged capsules) without reported injuries or deaths, fitting the criteria for a moderate severity recall.

Plain-English summary

Pfizer Inc. is recalling 116,400 bottles of Lyrica (pregabalin) 75 mg capsules, 90-count, prescription only. The recall is due to the potential presence of deformed or damaged capsules in specific lots.

The affected product is distributed by Parke-Davis, Division of Pfizer Inc. The recall covers lots M07862 (Exp 05/2018) and M07865 (Exp 06/2018). The product was distributed nationwide and in Puerto Rico.

Consumers with these specific lots should stop using the product and contact their healthcare provider or pharmacist for guidance on replacement or disposal.

The recalled product

Product
LYRICA (PREGABALIN)
Brand
LYRICA
Manufacturer
Pfizer Inc.
Affected units
116,400

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (4)

  • Lot #: M07862
  • Exp 05/2018
  • M07865
  • Exp 06/2018

UPCs (1)

  • 0300711012683

Distribution

Distributed nationwide across the United States.

The notice also names 1 state specifically:

Part of a larger recall action

This product is one of 2 recalled by Pfizer Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.

See all 2 products in this recall →

Same brand · LYRICA